세계의 신경병증성 통증 시장 보고서(2025년)

Neuropathic pain, a persistent condition resulting from nervous system damage or dysfunction, is characterized by sensations like burning, tingling, shooting, or electric shocks. Treating neuropathic pain can be complex, with causes including nerve injuries, diabetes, multiple sclerosis, nerve compression, neural degeneration, and central nervous system disorders.

The primary approaches to neuropathic pain treatment include medications and multimodal therapy. Medications involve the use of pharmaceutical substances to alleviate symptoms and manage conditions. Certain drugs, such as anticonvulsants, antidepressants, and opioids, are effective in targeting nerve-related abnormalities and pathways. They work to reduce the intensity of neuropathic pain signals, offering relief. Neuropathic pain diagnosis typically involves imaging, blood tests, and physical examinations. These diagnostic procedures are relevant for conditions like diabetic neuropathy, spinal stenosis, chemotherapy-induced peripheral neuropathy, and others. They are commonly administered in healthcare settings such as hospitals, clinics, home healthcare, and ambulatory surgical centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The neuropathic pain market research report is one of a series of new reports from The Business Research Company that provides neuropathic pain market statistics, including neuropathic pain industry global market size, regional shares, competitors with a neuropathic pain market share, detailed neuropathic pain market segments, market trends and opportunities and any further data you may need to thrive in the neuropathic pain industry. This neuropathic pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neuropathic pain market size has grown strongly in recent years. It will grow from $5.35 billion in 2024 to $5.78 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing demand for neuropathic pain drugs, chronic pain epidemic, growing demand for prescription treatments, government initiatives.

The neuropathic pain market size is expected to see strong growth in the next few years. It will grow to $7.78 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growing awareness of neuropathic pain, aging population, well-proliferated healthcare sector, accessibility to neuropathic pain treatments. Major trends in the forecast period include improved diagnostics, advancements in pain management, advancements in medical research, new drug approvals, strategic initiatives.

The forecast of 7.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. pain management by increasing costs for spinal cord stimulator components and compounded topical analgesics imported from Israel and the Netherlands, potentially reducing treatment efficacy and raising chronic pain care expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of chronic pain is expected to drive the growth of the neuropathic pain market. Chronic pain is ongoing and persistent pain that continues beyond the typical healing period for an injury or illness, lasting at least three to six months or more. The rising incidence of chronic pain, including neuropathic conditions, highlights the need for effective treatments, driving research, innovation, and investment in new therapies aimed at improving symptom relief and quality of life. For example, in December 2023, the Scottish Health Survey 2022, published by the Scottish Government, revealed that over one-third (38%) of adults in Scotland reported experiencing pain or discomfort lasting three months or longer, with a higher prevalence in women (43%) compared to men (33%). As a result, the increasing prevalence of chronic pain is fueling the growth of the neuropathic pain market.

The anticipated rise in diabetes cases is expected to drive the growth of the neuropathic pain market. Diabetes is a chronic condition characterized by high blood glucose levels. One of its most common complications is diabetic neuropathy, with more than 50% of diabetic patients experiencing some form of neuropathy during their lifetime. Diabetic peripheral neuropathy (DPN) is the most common type of neuropathy and is associated with established treatment methods. For example, in June 2024, the National Health Service (NHS), a UK-based government department, reported a significant rise in diabetes cases among individuals under 40, increasing from 173,166 in 2022 to 216,440 in 2023. This sharp rise highlights the growing prevalence of diabetes, especially among younger populations. As a result, the increasing number of diabetes cases is driving the growth of the neuropathic pain market.

The leading companies in the neuropathic pain market are embracing artificial intelligence technologies to revolutionize various facets of pain management. These innovations encompass advanced diagnosis, tailored treatment plans, real-time monitoring, drug discovery, and data-driven insights, all aimed at optimizing patient outcomes and refining pain management strategies. For instance, in March 2023, Nevro Corp., a U.S.-based medical device company, introduced the Senza HFX iQ spinal cord stimulation (SCS) system. This cutting-edge technology harnesses the power of artificial intelligence (AI) to deliver customized pain relief solutions for individual patients. The system, which comprises the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, is designed to address non-surgical back pain and painful diabetic neuropathy by adapting to patient responses and feedback. Utilizing a unique algorithm informed by extensive patient data, the system allows patients to fine-tune their pain relief programs through a smartphone app. The digital ecosystem of the system enables continuous data collection and potential updates. The primary goal of this technology is to elevate pain relief by offering consistency and personalization, representing a significant advancement in SCS therapy.

In July 2023, Novartis AG, a Switzerland-based multinational pharmaceutical company specializing in innovative medicines, acquired DTx Pharma for an undisclosed amount. This acquisition enables Novartis to leverage DTx's expertise in small interfering ribonucleic acid (siRNA) therapies for neurological disorders, strengthening its ability to address unmet medical needs and accelerate the development of new treatments for patients. DTx Pharma, a US-based preclinical biotechnology company, focuses on developing RNA-based therapies for neuropathic pain.

Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Medtronic Inc., Eli Lilly and Company, Stryker Corporation, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Biogen Inc., Zimmer Biomet Holdings Inc., Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grunenthal GmbH, Lupin Ltd., NuVasive Inc., Integer Holdings Corporation, Avanos Medical Inc., Orthofix Medical Inc., Nevro Corp., InvaGen Pharmaceuticals Inc., B. Braun Melsungen AG, Cirtec Medical Corp., Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, DePuy Synthes.

North America was the largest region in the neuropathic pain market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuropathic pain report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neuropathic pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neuropathic pain market consists of revenues earned by entities by providing physical therapy services, acupuncture services and relaxation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuropathic pain market also includes sales of anticonvulsants, antidepressants, opioids, topical creams and transcutaneous electrical nerve stimulation devices, which are used in providing neuropathic pain diagnosis and treatment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neuropathic Pain Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neuropathic pain market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neuropathic pain ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neuropathic pain market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Medications; Multimodal Therapy
• 2) By Diagnosis: Imaging; Blood Tests And Physical Examination
• 3) By Indication: Diabetic Neuropathy; Spinal Stenosis; Chemotherapy-Induced Peripheral Neuropathy; Other Indications
• 4) By End User: Hospitals; Clinics; Home Healthcare; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Medications: Anticonvulsants; Antidepressants; Opioids; Topical Treatments; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 2) By Multimodal Therapy: Combination Of Medications; Physical Therapy; Psychological Therapy; Lifestyle Modifications; Complementary Therapies
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; Sanofi S.A.; Bristol-Myers Squibb Company; Abbott Laboratories; GlaxoSmithKline Plc; Medtronic Inc.; Eli Lilly and Company; Stryker Corporation; Baxter International Inc.; Teva Pharmaceutical Industries Ltd; Boston Scientific Corporation; Biogen Inc.; Zimmer Biomet Holdings Inc. ; Sun Pharmaceutical Industries Ltd.; Mallinckrodt Pharmaceuticals; Grunenthal GmbH; Lupin Ltd.; NuVasive Inc.; Integer Holdings Corporation; Avanos Medical Inc.; Orthofix Medical Inc.; Nevro Corp.; InvaGen Pharmaceuticals Inc; B. Braun Melsungen AG; Cirtec Medical Corp.; Centaur Pharmaceuticals Pvt Ltd.; Stimwave LLC; DePuy Synthes
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neuropathic Pain Market Characteristics

3. Neuropathic Pain Market Trends And Strategies

4. Neuropathic Pain Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Neuropathic Pain Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neuropathic Pain PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neuropathic Pain Market Growth Rate Analysis
• 5.4. Global Neuropathic Pain Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neuropathic Pain Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neuropathic Pain Total Addressable Market (TAM)

6. Neuropathic Pain Market Segmentation

• 6.1. Global Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Multimodal Therapy
• 6.2. Global Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging
• Blood Tests And Physical Examination
• 6.3. Global Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diabetic Neuropathy
• Spinal Stenosis
• Chemotherapy-Induced Peripheral Neuropathy
• Other Indications
• 6.4. Global Neuropathic Pain Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Healthcare
• Ambulatory Surgical Centers
• Other End Users
• 6.5. Global Neuropathic Pain Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anticonvulsants
• Antidepressants
• Opioids
• Topical Treatments
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 6.6. Global Neuropathic Pain Market, Sub-Segmentation Of Multimodal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Of Medications
• Physical Therapy
• Psychological Therapy
• Lifestyle Modifications
• Complementary Therapies

7. Neuropathic Pain Market Regional And Country Analysis

• 7.1. Global Neuropathic Pain Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neuropathic Pain Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neuropathic Pain Market

• 8.1. Asia-Pacific Neuropathic Pain Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neuropathic Pain Market

• 9.1. China Neuropathic Pain Market Overview
• 9.2. China Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neuropathic Pain Market

• 10.1. India Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neuropathic Pain Market

• 11.1. Japan Neuropathic Pain Market Overview
• 11.2. Japan Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neuropathic Pain Market

• 12.1. Australia Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neuropathic Pain Market

• 13.1. Indonesia Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neuropathic Pain Market

• 14.1. South Korea Neuropathic Pain Market Overview
• 14.2. South Korea Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neuropathic Pain Market

• 15.1. Western Europe Neuropathic Pain Market Overview
• 15.2. Western Europe Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neuropathic Pain Market

• 16.1. UK Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neuropathic Pain Market

• 17.1. Germany Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neuropathic Pain Market

• 18.1. France Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neuropathic Pain Market

• 19.1. Italy Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neuropathic Pain Market

• 20.1. Spain Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neuropathic Pain Market

• 21.1. Eastern Europe Neuropathic Pain Market Overview
• 21.2. Eastern Europe Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neuropathic Pain Market

• 22.1. Russia Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neuropathic Pain Market

• 23.1. North America Neuropathic Pain Market Overview
• 23.2. North America Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neuropathic Pain Market

• 24.1. USA Neuropathic Pain Market Overview
• 24.2. USA Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neuropathic Pain Market

• 25.1. Canada Neuropathic Pain Market Overview
• 25.2. Canada Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neuropathic Pain Market

• 26.1. South America Neuropathic Pain Market Overview
• 26.2. South America Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neuropathic Pain Market

• 27.1. Brazil Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neuropathic Pain Market

• 28.1. Middle East Neuropathic Pain Market Overview
• 28.2. Middle East Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neuropathic Pain Market

• 29.1. Africa Neuropathic Pain Market Overview
• 29.2. Africa Neuropathic Pain Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neuropathic Pain Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neuropathic Pain Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neuropathic Pain Market Competitive Landscape And Company Profiles

• 30.1. Neuropathic Pain Market Competitive Landscape
• 30.2. Neuropathic Pain Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Neuropathic Pain Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline Plc
• 31.2. Medtronic Inc.
• 31.3. Eli Lilly and Company
• 31.4. Stryker Corporation
• 31.5. Baxter International Inc.
• 31.6. Teva Pharmaceutical Industries Ltd
• 31.7. Boston Scientific Corporation
• 31.8. Biogen Inc.
• 31.9. Zimmer Biomet Holdings Inc.
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Mallinckrodt Pharmaceuticals
• 31.12. Grunenthal GmbH
• 31.13. Lupin Ltd.
• 31.14. NuVasive Inc.
• 31.15. Integer Holdings Corporation

32. Global Neuropathic Pain Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuropathic Pain Market

34. Recent Developments In The Neuropathic Pain Market

35. Neuropathic Pain Market High Potential Countries, Segments and Strategies

• 35.1 Neuropathic Pain Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neuropathic Pain Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neuropathic Pain Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer